Literature DB >> 21487657

Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome.

Surabi Veeraragavan1, Nghiem Bui, Jennie R Perkins, Lisa A Yuva-Paylor, Randall L Carpenter, Richard Paylor.   

Abstract

RATIONALE: Muscarinic acetylcholine receptors (mAChR) are G protein-coupled receptors, widely expressed in the CNS. Electrophysiological and molecular studies have provided evidence for overactive M1 receptor signaling in the fragile X knockout (Fmr1 KO) mouse model, suggesting the involvement of the M1 receptors in fragile X syndrome. Overactive signaling through the M1 receptor has been hypothesized to contribute to the phenotypes seen in fragile X mice.
OBJECTIVE: We investigated the modulation of behavioral responses in the Fmr1 KO animals by reducing the activity through the muscarinic M1 receptor using the pharmacological agent dicyclomine, an M1 antagonist.
METHODS: The behavioral assays used to investigate the pharmacological effects include marble burying (perseverative behavior), open-field exploration (activity), passive avoidance (learning and memory), prepulse inhibition (sensorimotor gating), and audiogenic seizures.
RESULTS: Data from the marble-burying assay suggests that treatment with dicyclomine results in a decrease in the number of marbles buried in the wild-type and in the KO animals. To examine the possibility of drug-induced sedation, overall activity was measured in an open-field chamber. Dicyclomine only increases activity at a dose of 20 mg/kg in the wild-type mice but did not affect exploration in the KO animals. Lastly, we observed that dicyclomine causes a significant decrease in the percentage of audiogenic seizures in the Fmr1 KO animals.
CONCLUSION: Our findings suggest that pharmacologically reducing the activity through the mAChR M1 alters select behavioral responses in the Fmr1 KO mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21487657     DOI: 10.1007/s00213-011-2276-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  54 in total

1.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.

Authors:  A I Levey; C A Kitt; W F Simonds; D L Price; M R Brann
Journal:  J Neurosci       Date:  1991-10       Impact factor: 6.167

Review 2.  Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents.

Authors:  Jan Adriaan Bouwknecht; Richard Paylor
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

Review 3.  Molecular biology of muscarinic acetylcholine receptors.

Authors:  J Wess
Journal:  Crit Rev Neurobiol       Date:  1996

Review 4.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

5.  Mildly impaired water maze performance in male Fmr1 knockout mice.

Authors:  R D'Hooge; G Nagels; F Franck; C E Bakker; E Reyniers; K Storm; R F Kooy; B A Oostra; P J Willems; P P De Deyn
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

6.  Fragile X mice develop sensory hyperreactivity to auditory stimuli.

Authors:  L Chen; M Toth
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.

Authors:  C Ghelardini; N Galeotti; F Gualtieri; V Marchese; C Bellucci; A Bartolini
Journal:  J Pharmacol Exp Ther       Date:  1998-03       Impact factor: 4.030

Review 8.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

9.  Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene.

Authors:  Corinne M Spencer; Deanna F Graham; Lisa A Yuva-Paylor; David L Nelson; Richard Paylor
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

10.  Dicyclomine discriminates between M1- and M2-muscarinic receptors in the guinea-pig ileum.

Authors:  H Kilbinger; A Stein
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

View more
  29 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

2.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

Review 3.  The autism diagnosis in translation: shared affect in children and mouse models of ASD.

Authors:  Somer L Bishop; Garet P Lahvis
Journal:  Autism Res       Date:  2011-08-31       Impact factor: 5.216

4.  The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Richard Paylor
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

5.  Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.

Authors:  Bruce J Melancon; Thomas J Utley; Christian Sevel; Margrith E Mattmann; Yiu-Yin Cheung; Thomas M Bridges; Ryan D Morrison; Douglas J Sheffler; Colleen M Niswender; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2012-06-15       Impact factor: 2.823

6.  Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.

Authors:  Jamiela Kokash; Erin M Alderson; Sarah M Reinhard; Cynthia A Crawford; Devin K Binder; Iryna M Ethell; Khaleel A Razak
Journal:  Brain Res       Date:  2019-05-22       Impact factor: 3.252

7.  Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors.

Authors:  Dionisio A Amodeo; Joshua H Jones; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-10-28       Impact factor: 3.332

Review 8.  Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome.

Authors:  Lawrence K Fung; Eve-Marie Quintin; Brian W Haas; Allan L Reiss
Journal:  Curr Opin Neurol       Date:  2012-04       Impact factor: 5.710

9.  Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS).

Authors:  Surabi Veeraragavan; Deanna Graham; Nghiem Bui; Lisa A Yuva-Paylor; Jürgen Wess; Richard Paylor
Journal:  Behav Brain Res       Date:  2011-11-23       Impact factor: 3.332

10.  Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.

Authors:  Bruce J Melancon; Alexander P Lamers; Thomas M Bridges; Gary A Sulikowski; Thomas J Utley; Douglas J Sheffler; Meredith J Noetzel; Ryan D Morrison; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2011-12-06       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.